Evaluation of the intestinal microbiota and short-chain fatty acids content in patients with chronic inflammatory bowel diseases

Main Article Content

M.V. Stoykevich
N.S. Fedorova
N.V. Nedzvetskaya
I.A. Klenina
O.M. Tatarchuk

Abstract

Background. The pathogenesis of chronic inflammatory bowel disease (IBD) is still not fully clarified. It is known that disorders of the intestinal microbiota lead to an increased intestinal permeability, activation of mucous and adaptive immunity, impaired production and intestinal absorption of short-chain fatty acids (SCFA). The ratio of acetic, propionic, butyric acids is an important indicator of the integrity of the intestinal microbial community. Thus, the study of the composition of the intestinal microbiota and the concentrations of fecal SCFA is a very promi­sing approach to broadening the understanding of IBD pathoge­nesis. The purpose of our study was to determine the features of the production of fecal SCFA and the composition of colon microbiota in patients with IBD. Materials and methods. The study, which was carried out at the Department of Intestinal Diseases of the Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine, involved 74 patients with IBD with an average age of (43.2 ± 1.8) years, who according to nosology were divided into 2 groups: group I — those with ulcerative colitis (UC) (n = 66), group II — individuals with Crohn’s disease (CD) (n = 8). The diagnoses of CD and UC were established accor­ding to generally accepted diagnostic standards in gastroenterology. Determination of fecal SCFA was carried out by chromatographic method with the use of hardware-software complex for medical researches on the basis of the gas chromatographer Chromateс Crystal 5000. The intestinal microflora was evaluated using a microbiological study of the colon content. Results. Patients with IBD had significant changes in the spectrum of SCFA, which were similar in both UC and CD: a decrease in acetic acid in the UC group by 5.7 times, in the CD group by 10.5 times (p < 0.05), butyric acid in the UC group by 1.6 times, in the CD group by 1.5 times (p < 0.05), and an increase in propionic acid in the UC group by 4 times and in the CD group by 3.3 times (p < 0.05) compared with the control group. There was also a significant increase in the anaerobic index in patients with IBD. Microbiological study of feces showed a significant decrease in Lactobacillus, which was observed in all patients with IBD, as well as a decrease in Bifidobacterium in 19.7 % of those with UC and in 37.5 % with CD. There was a decrease of other representatives of the normal microflora: Enterococci (in 15.2 % in the UC group and 25 % in the CD group) and Escherichia coli (in 15.2 % in the UC group and 12.5 % in the CD group). Excessive growth of opportunistic flora was also detected: hemolytic Escherichia coli was increased in 19.7 % of patients with UC and in 12.5 % of those with CD; Proteus was detected in 12.1 % of people with UC and in 37.5 % with CD. The excessive growth of Candida was found in 43.9 % of patients in the UC group and in 87.5 % of indivi­duals with CD. Conclusions. Quantitative and qualitative deviations of the intestinal microbiota, such as a decrease in the number of major symbionts and an increase in the number of opportunistic pathogens, were observed in all examined patients with IBD. The obtained results showed that changes in SCFA concentrations in both nosologies of IBD differed significantly from those in the control group, which in combination with primary genetic defects of the barrier function of the epithelium and its regenerative abi­lity can lead to deterioration in the course and prognosis of IBD. Evalua­tion of the ratio of SCFA fractions with the calculation of the anaerobic index may be useful for the diagnosis of intestinal dysbiosis in patients with IBD.

Article Details

How to Cite
Stoykevich, M., Fedorova, N., Nedzvetskaya, N., Klenina, I., & Tatarchuk, O. (2021). Evaluation of the intestinal microbiota and short-chain fatty acids content in patients with chronic inflammatory bowel diseases. GASTROENTEROLOGY, 55(2), 98–103. https://doi.org/10.22141/2308-2097.55.2.2021.233631
Section
Original Researches

References

Maaser C, Sturm A, Vavricka SR, et al; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019 Feb 1;13(2):144-164. doi:10.1093/ecco-jcc/jjy113.

Dmochowska N, Wardill HR, Hughes PA. Advances in Imaging Specific Mediators of Inflammatory Bowel Disease. Int J Mol Sci. 2018 Aug 21;19(9):2471. doi:10.3390/ijms19092471.

Su HJ, Chiu YT, Chiu CT, et al. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. J Formos Med Assoc. 2019 Jul;118(7):1083-1092. doi:10.1016/j.jfma.2018.07.005.

Foster A, Jacobson K. Changing incidence of inflammatory bowel disease: environmental influences and lessons learnt from the South asian population. Front Pediatr. 2013 Nov 6;1:34. doi:10.3389/fped.2013.00034.

de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016 Jan;13(1):13-27. doi:10.1038/nrgastro.2015.186.

Rosen CE, Palm NW. Navigating the Microbiota Seas: Triangulation Finds a Way Forward. Cell Host Microbe. 2018 Jan 10;23(1):1-3. doi:10.1016/j.chom.2017.12.015.

Tlaskalová-Hogenová H, Stěpánková R, Kozáková H, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011 Mar;8(2):110-20. doi:10.1038/cmi.2010.67.

Hoffmann C, Dollive S, Grunberg S, et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One. 2013 Jun 17;8(6):e66019. doi:10.1371/journal.pone.0066019. 

Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell. 2012 Mar 16;148(6):1258-70. doi:10.1016/j.cell.2012.01.035.

Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol. 2015 Jan;31(1):69-75. doi:10.1097/MOG.0000000000000139.

Wu W, Chen F, Liu Z, Cong Y. Microbiota-specific Th17 Cells: Yin and Yang in Regulation of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Jun;22(6):1473-82. doi:10.1097/MIB.0000000000000775.

Bäumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature. 2016 Jul 7;535(7610):85-93. doi:10.1038/nature18849.

Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010 Jun 28;16(24):2978-90. doi:10.3748/wjg.v16.i24.2978.

Stepanov YuM, Fedorova NS, Zyhalo EV. The efficiency of rifaximin in the correction of the small intestinal bacterial overgrowth syndrome in chronic inflammatory bowel diseases and functional bowel disorders. Gastroenterology. 2019;53(4):246-251. doi:10.22141/2308-2097.53.4.2019.182740. (in Ukrainian).

den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013 Sep;54(9):2325-40. doi:10.1194/jlr.R036012.

Haenen D, Zhang J, Souza da Silva C, et al. A diet high in resistant starch modulates microbiota composition, SCFA concentrations, and gene expression in pig intestine. J Nutr. 2013 Mar;143(3):274-83. doi:10.3945/jn.112.169672.

Sun M, Wu W, Liu Z, Cong Y. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. J Gastroenterol. 2017 Jan;52(1):1-8. doi:10.1007/s00535-016-1242-9.

Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91-119. doi:10.1016/B978-0-12-800100-4.00003-9.

Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients. 2011 Oct;3(10):858-76. doi:10.3390/nu3100858.

Zhao G, Nyman M, Jönsson JA. Rapid determination of short-chain fatty acids in colonic contents and faeces of humans and rats by acidified water-extraction and direct-injection gas chromatography. Biomed Chromatogr. 2006 Aug;20(8):674-82. doi:10.1002/bmc.580.

Alyoshkin VA, Selkova EP, Zatevalov AM, MironovAYu., Volchetsky AL, Gudova NV. Determination of dysbiotic changes in the gastrointestinal tract by markers of intestinal contents - Federal clinical guidelines. N Novgorod: Publishing House Remediium Volga Region; 2016. 40p. (in Russian).

Golovenko OV, Halif IL, Golovenko AO. Role Of Butyric Acid In The Treatment Of Patients With Organic And Functional Bowel Diseases. Modern Gastroenterology. 2011;4:124-134. (in Ukrainian). Available from: http://sgastro.vitapol.com.ua/svizhij_nomer.php?nid=60.

Farup PG, Rudi K, Hestad K. Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome? BMC Gastroenterol. 2016 Apr 27;16(1):51. doi:10.1186/s12876-016-0446-z.

Most read articles by the same author(s)

<< < 1 2 3 4 5 > >>